보고서 요약(국문)

보고서 개요
글로벌 G7 척수소뇌실조증 시장은 2023년 2억 3,760만 달러에 달했으며, 2024년부터 2031년까지 연평균 6.3%의 성장률을 보이며 2031년에는 3억 8,510만 달러에 이를 것으로 예상됩니다.
척수소뇌실조증(SCA)은 주로 소뇌에 영향을 미치는 유전성(상염색체 우성) 진행성 신경퇴행성 질환으로, 다양한 유전형을 나타냅니다. SCA는 유전성 소뇌실조증의 하위 유형이며 희귀 질환입니다. 현재까지 40개 이상의 서로 다른 유전적 SCA가 확인되었으며, 이는 발견된 유전적 위치에 따라 분류됩니다. SCA1은 최초로 기술된 SCA이며, 이후 여러 하위 유형이 순차적으로 확인되었습니다. SCA는 반드시 소뇌와 척수에만 국한되는 질환은 아닙니다. 중추신경계의 다른 부분, 예를 들어 교뇌핵, 척수, 말초신경, 대뇌피질, 기저핵 등에도 영향을 미칠 수 있습니다.
SCA7은 아탁신 7(ATXN7) 유전자의 돌연변이로 인해 CAG 삼핵산 반복 서열이 확장되어 발생합니다. 척수소뇌실조증의 정확한 병인은 아직 밝혀지지 않았습니다. 그러나 여러 연구에서 SCA의 일반적인 기전으로 비정상적인 단백질 생성을 유발하는 유전자 돌연변이, 전사 조절 장애, 자가포식 기능 장애, 채널병증, 미토콘드리아 기능 장애, 독성 RNA 기능 획득 등이 제시되었습니다.
시장 동향: 성장 요인
G7 척수소뇌실조증 유병률 증가
전 세계 G7 척수소뇌실조증 시장의 수요는 여러 요인에 의해 주도되고 있습니다. G7 척수소뇌실조증 유병률 증가와 기술 발전이 시장 성장을 견인하고 있습니다.

예를 들어, 미국 국립보건원(NIH)에 발표된 기사에 따르면, SCA7은 주로 북유럽인과 아프리카인이라는 두 인종 집단에서 발생합니다. 실제로 SCA7은 헌팅턴병 유사 2형(HDL2)을 제외하고는 아프리카계 인종에서 발병률이 높은 유일한 반복 확장 질환입니다. 이러한 이유로 미국에서 SCA7 환자의 상당수가 아프리카계 인종입니다. 전 세계적으로 SCA7은 북미, 유럽, 유라시아, 호주, 남아프리카, 남미에서 발생합니다.
전 세계적으로 이 질환의 유병률은 10만 명당 1명 미만으로 추정되며, 모든 형태의 소뇌척수성 운동실조증의 2~4%를 차지하는 것으로 여겨집니다(아시아 인구에서는 최대 7%). 스칸디나비아나 남아프리카와 같은 일부 인구 집단에서는 유병률이 더 높습니다.

제약 요인
치료와 관련된 높은 비용, 질병에 대한 인식 부족, 새로운 치료법 승인을 위한 엄격한 규제 요건 등의 요인이 시장 성장을 저해할 것으로 예상됩니다. 현재까지 G7 척수소뇌성 운동실조증에 대한 완치법은 없지만, 증상 관리를 통해 질병의 상태를 개선할 수 있습니다.
시장 세분화 분석
전 세계 G7 척수소뇌성 운동실조증 시장은 치료법, 최종 사용자 및 지역별로 세분화됩니다.
의약품 부문은 전 세계 G7 척수소뇌성 운동실조증 시장 점유율의 약 56.3%를 차지했습니다.
의약품 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 이 부문에서는 기술 발전이 시장 성장을 견인할 것입니다.
아만타딘, 부스피론, 릴루졸은 G7 척수소뇌성 운동실조증의 증상 및 증상 치료에 가장 널리 사용되는 약물입니다. 아만타딘은 항바이러스제로 사용되는 아다만탄 계열 약물입니다. 부스피론은 항바이러스제, 도파민 작용제, 진통제, NMDA 수용체 길항제, 비마약성 진통제로서의 역할을 합니다. 주요 지방족 아민이며 아다만탄 계열 화합물입니다. 아다만탄-1-아미늄의 짝염기이며, 아다만탄의 수소화물로부터 유래합니다.
부스피론은 주로 범불안 장애 치료에 사용됩니다. 미국 식품의약국(FDA)의 승인을 받은 불안 장애 관리 또는 불안 증상의 단기 완화용 의약품입니다.
시장 지역 분석
북미는 전 세계 G7 척수소뇌성 운동실조증 시장에서 약 39.3%의 시장 점유율을 차지했습니다.
북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 이 지역의 기술 발전이 시장 성장을 견인하고 있습니다.

CRISPR/Cas9 시스템은 유도 만능 줄기세포에서 확장된 CAG 반복 서열을 제거하는 데 사용되어 왔으며, 향후 SCA 7 치료에 적용될 수 있을 것으로 예상됩니다. ASO 기반 치료법이 SCA 치료를 위해 개발되고 있지만, 치료 반응을 평가하기 위한 바이오마커를 식별해야 합니다.
시장 세분화
치료 유형별
물리 및 작업 치료
약물
아만타딘
부스피론
릴루졸
언어 치료
시력 및 안과 치료
기타
유전자 치료
줄기세포 치료
최종 사용자별
병원
전문 클리닉
기타
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
스페인
이탈리아
기타 유럽 지역
남미
브라질
아르헨티나
기타 남미 지역
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양 지역
중동 및 아프리카
시장 경쟁 환경
전 세계 G7 척수소뇌실조증 시장의 주요 글로벌 기업으로는 Teva Pharmaceuticals Inc., Sanofi, Dynatronics Corporation 등이 있습니다. Kinetec Medical Products Ltd, EMS Physio Ltd, DJO Global Inc., Enraf-Nonius BV, Zynex Medical Inc., BTL Corporate, Life Care Systems 등이 주요 기업입니다.

보고서 구매 이유:
치료법, 최종 사용자, 지역별 글로벌 G7 척수소뇌성 운동실조증 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.
모든 세그먼트를 포함한 글로벌 G7 척수소뇌성 운동실조증 시장의 다양한 데이터 포인트가 담긴 Excel 데이터 시트를 제공합니다.
PDF 보고서는 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석 결과를 담고 있습니다.
모든 주요 기업의 핵심 제품을 포함하는 제품 매핑 Excel 파일을 제공합니다.
글로벌 G7 척수소뇌성 운동실조증 시장 보고서는 약 51개의 표, 54개의 그림, 181페이지로 구성됩니다.

2024년 목표 고객층
제조업체/구매자
산업 투자자/투자은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global G7 Spinocerebellar Ataxia Market reached US$ 237.6 million in 2023 and is expected to reach US$ 385.1 million by 2031, growing at a CAGR of 6.3% during the forecast period 2024-2031.
Spinocerebellar ataxia (SCA) is an inherited (autosomal dominant), progressive, neurodegenerative, and heterogeneous disease that mainly affects the cerebellum. SCA is a subset of hereditary cerebellar ataxia and is a rare disease. To date, more than 40 distinct genetic SCAs have been identified which are classified according to the genetic loci in order of identification. SCA1 was the first SCA described and then further subtypes are identified sequentially. SCA doesn't compulsorily mean that it is restricted to the cerebellum and spinal cord. It may involve the other parts of the central nervous system as well, such as pontine nuclei, spinal cord, peripheral nerves, cortex, basal ganglia, etc.
SCA7 is caused by a mutation in the ataxin 7 (ATXN7) gene that leads to an expansion of a CAG trinucleotide repeat. The exact pathogenesis of spinocerebellar ataxia is still not known. However many study series promulgated that common mechanisms of SCA are genetic mutations causing abnormal protein products, transcriptional dysregulation, dysfunction of autophagy, channelopathies, mitochondrial dysfunction, and toxic RNA gain of function.
Market Dynamics: Drivers
Increasing prevalence of G7 spinocerebellar ataxia
The demand for the global G7 spinocerebellar ataxia market is driven by multiple factors. The rising prevalence of G7 spinocerebellar ataxia and technological advancements propel the market growth.
For instance, according to an article published by nih.gov, SCA7 occurs predominantly in two racial population groups, northern Europeans and Africans. Indeed, SCA7 is the only repeat expansion disease, with the exception of Huntington disease-like 2 (HDL2), with a large number of affected individuals of African racial ancestry. For this reason, a substantial fraction of individuals with SCA7 in the United States are of African racial ancestry. Worldwide, SCA7 is seen in North America, Europe, Eurasia, Australia, South Africa, and South America.
The worldwide prevalence of the disease is estimated to be less than 1/100,000 and it is thought to account for 2-4 % of all forms of spinocerebellar ataxia (up to 7 % in Asian populations). Higher prevalence is found in some populations such as in Scandinavia or South Africa.
Restraints
Factors such as the high cost associated with the treatment, lack of awareness among people, and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. There is no cure for G7 spinocerebellar ataxia to date, but managing the symptoms can help make the condition of the disease better.
Market Segment Analysis
The global G7 spinocerebellar ataxia market is segmented based on treatment, end-user, and region.
The segment drugs accounted for approximately 56.3% of the global G7 spinocerebellar ataxia market share
The drugs segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements would drive this market.
Amantadine, Buspirone, and Riluzole are the most widely used drugs in treating symptoms and effects of G7 spinocerebellar ataxia market. Amantadine is a member of the class of adamantanes that is used as an antiviral. It has a role as an antiviral drug, a dopaminergic agent, an analgesic, an NMDA receptor antagonist, and a non-narcotic analgesic. It is a primary aliphatic amine and a member of adamantanes. It is a conjugate base of an adamantan-1-aminium. It derives from the hydride of an adamantane.
Buspirone is primarily used to treat generalized anxiety disorder. It is a United States Food and Drug Administration-approved medicine for managing anxiety disorders or the short-term relief of anxiety symptoms.
Market Geographical Analysis
North America accounted for approximately 39.3% of the global G7 spinocerebellar ataxia market market share
North America region is expected to hold the largest market share over the forecast period. The technological advancements in this region, help to propel the market.
The CRISPR/Cas9 system has been used to delete expanded CAG repeats in induced pluripotent stem cells, and may have future applications in the teeatment of SCA 7. ASO-based treatments are being developed for SCAs, but will require the identification of biomarkers to assess treatment response.
Market Segmentation
By Treatment
Physical and Occupational Therapy
Drugs
Amantadine
Buspirone
Riluzole
Speech and Language Therapy
Visual and Ocular Care
Others
Gene Therapy
Stem Cell Therapy
By End-User
Hospitals
Specialty Clinics
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the global G7 spinocerebellar ataxia market include Teva Pharmaceuticals Inc., Sanofi, Dynatronics Corporation, Kinetec Medical Products Ltd, EMS Physio Ltd, DJO Global Inc., Enraf-Nonius BV, Zynex Medical Inc., BTL Corporate, Life Care Systems among others.
Why Purchase the Report?
To visualize the global G7 spinocerebellar ataxia market segmentation based on treatment, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of global G7 spinocerebellar ataxia market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global G7 spinocerebellar ataxia market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment
3.2. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of SCA 7
4.1.1.2. Technological Advancements
4.1.2. Restraints
4.1.2.1. High Cost of Treatment
4.1.2.2. Lack of Awareness
4.1.2.3. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Treatment
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
6.1.2. Market Attractiveness Index, By Treatment
6.2. Physical and Occupational Therapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Drugs
6.4. Speech and Language Therapy
6.5. Visual and Ocular Care
6.6. Others
7. By End-User
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. UK
8.3.5.3. France
8.3.5.4. Italy
8.3.5.5. Spain
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. Teva Pharmaceuticals Inc. *
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. Sanofi
10.3. Dynatronics Corporation
10.4. Kinetic Medical Products Ltd.
10.5. EMS Physio Ltd.
10.6. DJO Global Inc.
10.7. Enraf-Nonius BV
10.8. Zynex Medical Inc.
10.9. BTL Corporate
10.10. Life Care Systems (*LIST NOT EXHAUSTIVE)
11. Appendix
11.1. About Us and Services
11.2. Contact Us

언급된 주요 기업들

Teva Pharmaceuticals Inc., 4.	Key Developments, Sanofi, Dynatronics Corporation, Kinetic Medical Products Ltd., EMS Physio Ltd., DJO Global Inc., Enraf-Nonius BV, Zynex Medical Inc., BTL Corporate

표 목록 (Tables)

List of Tables

Table 1 Global G7 Spinocerebellar Ataxia Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 2 Global G7 Spinocerebellar Ataxia Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 3 Global G7 Spinocerebellar Ataxia Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 4 Global G7 Spinocerebellar Ataxia Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 5 Global G7 Spinocerebellar Ataxia Market Value, By Treatment, 2022-2031 (US$ Million)

Table 6 Global G7 Spinocerebellar Ataxia Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 7 Global G7 Spinocerebellar Ataxia Market Value, By End-User, 2022-2031 (US$ Million)

Table 8 Global G7 Spinocerebellar Ataxia Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 9 Global G7 Spinocerebellar Ataxia Market Value, By Region, 2022-2031 (US$ Million)

Table 10 North America G7 Spinocerebellar Ataxia Market Value, By Treatment, 2022-2031 (US$ Million)

Table 11 North America G7 Spinocerebellar Ataxia Market Value, By End-User, 2022-2031 (US$ Million)

Table 12 North America G7 Spinocerebellar Ataxia Market Value, By Country, 2022-2031 (US$ Million)

Table 13 South America G7 Spinocerebellar Ataxia Market Value, By Treatment, 2022-2031 (US$ Million)

Table 14 South America G7 Spinocerebellar Ataxia Market Value, By End-User, 2022-2031 (US$ Million)

Table 15 South America G7 Spinocerebellar Ataxia Market Value, By Country, 2022-2031 (US$ Million)

Table 16 Europe G7 Spinocerebellar Ataxia Market Value, By Treatment, 2022-2031 (US$ Million)

Table 17 Europe G7 Spinocerebellar Ataxia Market Value, By End-User, 2022-2031 (US$ Million)

Table 18 Europe G7 Spinocerebellar Ataxia Market Value, By Country, 2022-2031 (US$ Million)

Table 19 Asia-Pacific G7 Spinocerebellar Ataxia Market Value, By Treatment, 2022-2031 (US$ Million)

Table 20 Asia-Pacific G7 Spinocerebellar Ataxia Market Value, By End-User, 2022-2031 (US$ Million)

Table 21 Asia-Pacific G7 Spinocerebellar Ataxia Market Value, By Country, 2022-2031 (US$ Million)

Table 22 Middle East and Africa G7 Spinocerebellar Ataxia Market Value, By Treatment, 2022-2031 (US$ Million)

Table 23 Middle East and Africa G7 Spinocerebellar Ataxia Market Value, By End-User, 2022-2031 (US$ Million)

Table 24 Middle East and Africa G7 Spinocerebellar Ataxia Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Teva Pharmaceuticals Inc.: Overview

Table 26 Teva Pharmaceuticals Inc.: Product Portfolio

Table 27 Teva Pharmaceuticals Inc.: Key Developments

Table 28 Sanofi: Overview

Table 29 Sanofi: Product Portfolio

Table 30 Sanofi: Key Developments

Table 31 Dynatronics Corporation: Overview

Table 32 Dynatronics Corporation: Product Portfolio

Table 33 Dynatronics Corporation: Key Developments

Table 34 Kinetec Medical Products Ltd: Overview

Table 35 Kinetec Medical Products Ltd: Product Portfolio

Table 36 Kinetec Medical Products Ltd: Key Developments

Table 37 EMS Physio Ltd: Overview

Table 38 EMS Physio Ltd: Product Portfolio

Table 39 EMS Physio Ltd: Key Developments

Table 40 DJO Global Inc.: Overview

Table 41 DJO Global Inc.: Product Portfolio

Table 42 DJO Global Inc.: Key Developments

Table 43 Enraf-Nonius BV: Overview

Table 44 Enraf-Nonius BV: Product Portfolio

Table 45 Enraf-Nonius BV: Key Developments

Table 46 Zynex Medical Inc.: Overview

Table 47 Zynex Medical Inc.: Product Portfolio

Table 48 Zynex Medical Inc.: Key Developments

Table 49 BTL Corporate: Overview

Table 50 BTL Corporate: Product Portfolio

Table 51 BTL Corporate: Key Developments

Table 52 Life Care Systems: Overview

Table 53 Life Care Systems: Product Portfolio

Table 54 Life Care Systems: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 2 Global G7 Spinocerebellar Ataxia Market Share, By Treatment, 2023 & 2031 (%)

Figure 3 Global G7 Spinocerebellar Ataxia Market Share, By End-User, 2023 & 2031 (%)

Figure 4 Global G7 Spinocerebellar Ataxia Market Share, By Region, 2023 & 2031 (%)

Figure 5 Global G7 Spinocerebellar Ataxia Market Y-o-Y Growth, By Treatment, 2023-2031 (%)

Figure 6 Physical and Occupational Therapy G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 7 Drugs G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 8 Speech and Language Therapy G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 9 Visual and Ocular Care G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 10 Others G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 11 Global G7 Spinocerebellar Ataxia Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 12 Hospitals End-User in Global G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 13 Specialty Clinics End-User in Global G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 14 Others End-User in Global G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 15 Global G7 Spinocerebellar Ataxia Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 16 North America G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 17 North America G7 Spinocerebellar Ataxia Market Share, By Treatment, 2023 & 2031 (%)

Figure 18 North America G7 Spinocerebellar Ataxia Market Share, By End-User, 2023 & 2031 (%)

Figure 19 North America G7 Spinocerebellar Ataxia Market Share, By Country, 2023 & 2031 (%)

Figure 20 South America G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 21 South America G7 Spinocerebellar Ataxia Market Share, By Treatment, 2023 & 2031 (%)

Figure 22 South America G7 Spinocerebellar Ataxia Market Share, By End-User, 2023 & 2031 (%)

Figure 23 South America G7 Spinocerebellar Ataxia Market Share, By Country, 2023 & 2031 (%)

Figure 24 Europe G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 25 Europe G7 Spinocerebellar Ataxia Market Share, By Treatment, 2023 & 2031 (%)

Figure 26 Europe G7 Spinocerebellar Ataxia Market Share, By End-User, 2023 & 2031 (%)

Figure 27 Europe G7 Spinocerebellar Ataxia Market Share, By Country, 2023 & 2031 (%)

Figure 28 Asia-Pacific G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 29 Asia-Pacific G7 Spinocerebellar Ataxia Market Share, By Treatment, 2023 & 2031 (%)

Figure 30 Asia-Pacific G7 Spinocerebellar Ataxia Market Share, By End-User, 2023 & 2031 (%)

Figure 31 Asia-Pacific G7 Spinocerebellar Ataxia Market Share, By Country, 2023 & 2031 (%)

Figure 32 Middle East and Africa G7 Spinocerebellar Ataxia Market Value, 2022-2031 (US$ Million)

Figure 33 Middle East and Africa G7 Spinocerebellar Ataxia Market Share, By Treatment, 2023 & 2031 (%)

Figure 34 Middle East and Africa G7 Spinocerebellar Ataxia Market Share, By End-User, 2023 & 2031 (%)

Figure 35 Teva Pharmaceuticals Inc.: Financials

Figure 36 Sanofi: Financials

Figure 37 Dynatronics Corporation: Financials

Figure 38 Kinetec Medical Products Ltd: Financials

Figure 39 EMS Physio Ltd: Financials

Figure 40 DJO Global Inc.: Financials

Figure 41 Enraf-Nonius BV: Financials

Figure 42 Zynex Medical Inc.: Financials

Figure 43 BTL Corporate: Financials

Figure 44 Life Care Systems: Financials

글로벌 G7 척수소뇌성 운동실조증 시장 – 2024년 – 2031년

Global G7 Spinocerebellar Ataxia Market - 2024 - 2031